This trial is active, not recruiting.

Conditions colorectal cancer, metastatic cancer
Treatments folfox regimen, fluorouracil, leucovorin calcium, oxaliplatin, adjuvant therapy, conventional surgery, neoadjuvant therapy
Phase phase 3
Sponsor European Organisation for Research and Treatment of Cancer - EORTC
Collaborator Australasian Gastro-Intestinal Trials Group
Start date September 2000
Trial identifier NCT00006479, AGITG-EORTC-40983, ALM-CAO-EORTC-40983, CDR0000068309, CRC-EORTC-40983, CRUK-LON-EORTC-40983, EORTC-40983, EU-20048, FFCD-EORTC-40983


RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and combining chemotherapy with surgery may kill more tumor cells. It is not yet known if surgery is more effective with or without chemotherapy for liver metastases.

PURPOSE: Randomized phase III trial to compare the effectiveness of surgery with or without combination chemotherapy in treating patients who have liver metastases from colorectal cancer.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Primary purpose treatment

Eligibility Criteria

Male or female participants from 18 years up to 80 years old.

DISEASE CHARACTERISTICS: - Diagnosis of potentially resectable colorectal liver metastases that meets one of the following criteria: - Metachronous metastases after complete resection of primary tumor without gross or microscopic evidence of residual disease - Synchronous metastases after complete resection of primary tumor more than 1 month before study - Synchronous metastases with sufficient evidence (i.e., CAT scan or diagnostic laparoscopy) that both the primary tumor and liver metastases can be completely resected during the same procedure and resection of primary may be delayed 3-4 months PATIENT CHARACTERISTICS: Age: - 18 to 80 Performance status: - WHO 0-2 - Karnofsky 60-100% Life expectancy: - Not specified Hematopoietic: - Absolute neutrophil count greater than 1,500/mm^3 - Platelet count greater than 100,000/mm^3 Hepatic: - No hepatic insufficiency Renal: - Creatinine less than 2 times upper limit of normal Cardiovascular: - No uncontrolled congestive heart failure or angina pectoris - No hypertension or arrhythmia Other: - No other malignancy within the past 10 years except adequately treated carcinoma in situ of the cervix or nonmelanoma skin cancer - No peripheral neuropathy greater than grade 1 - No prior significant neurologic or psychiatric disorders - No active infection - Not pregnant or nursing - Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: - No concurrent biologic therapy Chemotherapy: - No prior chemotherapy for advanced disease - Prior adjuvant chemotherapy for primary cancer allowed unless included oxaliplatin - No other concurrent chemotherapy Endocrine therapy: - No concurrent anticancer endocrine therapy Radiotherapy: - No concurrent radiotherapy Surgery: - See Disease Characteristics Other: - At least 30 days since prior investigational drugs - No concurrent investigational drugs

Additional Information

Official title Pre- and Post-Operative Chemotherapy With Oxaliplatin 5FU/LV Versus Surgery Alone in Resectable Liver Metastases From Colorectal Origin - Phase III Study
Description OBJECTIVES: - Compare the progression-free and overall survival of patients with resectable colorectal liver metastases treated with surgery with or without neoadjuvant and adjuvant oxaliplatin, fluorouracil, and leucovorin calcium. - Compare the percentage of patients with total resection with these two treatments. OUTLINE: This is a multicenter study. Patients are stratified according to participating center, prior adjuvant chemotherapy (yes vs no), plasma CEA level in ng/mL at diagnosis of liver metastases (5 or less vs 6 to 30 vs 31 or greater), serosa extension of primary cancer (absent T1 or T2 vs present T3 or T4), lymphatic spread of primary cancer (absent vs present N+), time interval between diagnosis of primary tumor to metastases (2 years or more vs fewer than 2 years), and number of metastases (1 to 3 vs 4). Patients are randomized to one of two treatment arms. - Arm I: Patients receive oxaliplatin IV over 2 hours on day 1 and leucovorin calcium (LV) IV over 2 hours followed by fluorouracil (5-FU) IV over 22 hours on days 1 and 2. Treatment repeats every 15 days for 6 courses in the absence of disease progression or unacceptable toxicity. At 2 to 5 weeks after chemotherapy, patients undergo liver resection. Patients with progressive disease after 3 courses of chemotherapy undergo liver resection at least 2 weeks after completion of course 3 and do not receive postoperative chemotherapy. At 2 to 5 weeks after surgery, patients receive oxaliplatin, LV, and 5-FU as in preoperative chemotherapy. - Arm II: Patients undergo liver resection. Patients are followed every 3 months for 2 years and then every 6 months thereafter. Peer Reviewed and Funded or Endorsed by Cancer Research UK PROJECTED ACCRUAL: A total of 330 patients (165 per arm) will be accrued for this study within 3 years.
Trial information was received from ClinicalTrials.gov and was last updated in April 2011.
Information provided to ClinicalTrials.gov by National Cancer Institute (NCI).